Tags: Drug.
Vorsetuzumab mafodotin (SGN-75) is an antibody-drug conjugate (ADC) directed to the protein CD70 designed for the treatment of cancer. It is a humanized monoclonal antibody vorsetuzumab conjugated with noncleavable monomethyl auristatin F (MMAF) a cytotoxic agent.This drug was developed by Seattle Genetics Inc. The drug completed phase I clinical trials for renal cell carcinoma but development was discontinued.